Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,957.50    33.00 (1.71%)
Bid:
1,961.00
Ask:
1,961.50
Spread: 0.50 (0.025%)
Market Cap: £78.45b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Total Voting Rights

1 Apr 2026 15:00

RNS Number : 1145Z
GSK PLC
01 April 2026
 

Issued: 1 April 2026, London UK

 

Total Voting Rights

 

 

 

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

 

The Company's issued share capital as at 31 March 2026 consisted of 4,316,179,781 shares of 31 ¼ pence each ('Ordinary Shares'), of which 256,112,615 Ordinary Shares were held in Treasury.

 

Therefore, the total number of voting rights in the Company is 4,060,067,166. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Notifications may be sent to company.secretary@gsk.com.

 

 

V A Whyte

Company Secretary

 

1 April 2026

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBXGDSBGGDGLB
Date   Source Headline
24th Feb 20223:12 pmRNSCanada Approval For Medicago GSK Covid-19 Vaccine
23rd Feb 20222:50 pmRNSDirector/PDMR Shareholding
22nd Feb 20222:00 pmRNSGSK Consumer Healthcare to be called Haleon
22nd Feb 20229:22 amRNSDirector/PDMR Shareholding
18th Feb 20224:30 pmRNSDirector/PDMR Shareholding
18th Feb 20227:00 amRNSGSK gives update on RSV maternal vaccine candidate
17th Feb 20224:00 pmRNSDirector/PDMR Shareholding
17th Feb 20223:40 pmRNSDirector/PDMR Shareholding
17th Feb 20223:20 pmRNSDirector/PDMR Shareholding
17th Feb 20222:50 pmRNSDirector/PDMR Shareholding
17th Feb 20222:19 pmRNSDirector/PDMR Shareholding
16th Feb 20226:04 pmRNSDirector/PDMR Shareholding
14th Feb 20225:50 pmRNSDirector/PDMR Shareholding
14th Feb 20221:26 pmRNSTransfer of Treasury Shares
11th Feb 20222:06 pmRNSDirector/PDMR Shareholding
11th Feb 20229:33 amRNSDirector/PDMR Shareholding
10th Feb 20229:00 amRNSBenlysta approved in China for Lupus Nephritis
9th Feb 202211:07 amRNSDirector/PDMR Shareholding
9th Feb 20227:00 amRNSFinal Results
7th Feb 202210:30 amRNSPublication of full year 2021 results: Replacement
7th Feb 202210:00 amRNSPublication of full year 2021 results
2nd Feb 20227:00 amRNSGSK announces settlement between ViiV and Gilead
1st Feb 20221:44 pmRNSFDA approves ViiV Healthcare’s sNDA for Cabenuva
1st Feb 202211:44 amRNSTotal Voting Rights
26th Jan 20224:48 pmRNSDirector/PDMR Shareholding
20th Jan 20223:59 pmRNSDirector/PDMR Shareholding
19th Jan 20224:33 pmRNSDirector/PDMR Shareholding
19th Jan 20223:14 pmRNSDirector/PDMR Shareholding
19th Jan 20223:10 pmRNSDirector/PDMR Shareholding
19th Jan 20227:00 amRNSTony Wood appointed CSO Designate, GSK
17th Jan 20225:04 pmRNSDirector/PDMR Shareholding
17th Jan 20223:07 pmRNSDirector/PDMR Shareholding
17th Jan 20227:00 amRNSUpdate - GSK Consumer Healthcare
14th Jan 20223:22 pmRNSDirector/PDMR Shareholding
13th Jan 20224:12 pmRNSDirector/PDMR Shareholding
11th Jan 20224:28 pmRNSDirector/PDMR Shareholding
11th Jan 202212:08 pmRNSUS Govt buys additional 600,000 sotrovimab doses
4th Jan 202212:28 pmRNSTotal Voting Rights
23rd Dec 20211:11 pmRNSDirector/PDMR Shareholding
22nd Dec 20212:57 pmRNSDirector/PDMR Shareholding
21st Dec 20217:00 amRNSViiV Healthcare announces FDA approval of Apretude
20th Dec 20217:00 amRNSConsumer Healthcare Chair Designate appointed
17th Dec 202112:48 pmRNSXevudy approved in Europe to treat COVID-19
15th Dec 20217:00 amRNSGSK/Sanofi COVID-19 vaccine booster & Ph3 update
13th Dec 202111:25 amRNSDirector/PDMR Shareholding
9th Dec 20214:35 pmRNSDirector/PDMR Shareholding
7th Dec 202112:00 pmRNSMedicago/GSK COVID-19 vaccine positive Ph3 data
7th Dec 20217:07 amRNSSotrovimab retains its activity vs Omicron variant
2nd Dec 20217:02 amRNSSotrovimab retains its activity vs Omicron variant
1st Dec 202111:05 amPRNTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.